Research published in the Journal of Alzheimer's Disease suggests findings could transform emergency protocols for the 2.5 ...

New research from the University of Virginia School of Medicine is revealing why traumatic brain injury increases the chance ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

In this webinar, Jonathan Schott and Alex Forrest-Hay will showcase how new biomarker assays for brain-derived pTau217 ...

In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...

We are approaching the end of 2025, a year of remarkable breakthroughs in medicine, technology, and lifestyle. From AI ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Conventional Alzheimer’s therapies often target only a single pathological feature, such as amyloid aggregation or oxidative ...

Music motivates and inspires and is a powerful and nonthreatening medium and therefore, people with Alzheimer’s react ...